摘要
目的探讨对晚期直肠癌实施卡培他滨单药或联合奥沙利铂同步放化疗的临床疗效。方法选取我院2013年1月～2017年6月间收治的100例晚期直肠癌患者实施观察研究,依随机数字表法将患者分为单药组(n=50)和联合组(n=50),对单药组采取卡培他滨化疗联合同步放疗,联合组采取卡培他滨联合奥沙利铂化疗同步放疗,分析总结两种治疗方式对患者治疗效果、机体状态、症状改善状况、生活质量、不良反应、1年内生存率的影响。结果联合组治疗总有效率74.0%明显高于单药组42.0%(P<0.05)。联合组治疗后KPS评分显著高于单药组(P<0.05)。联合组治疗后血便、便次减少、骶尾疼痛症状改善率显著高于单药组(P<0.05)。联合组治疗后情绪功能、角色功能、社会功能、认知功能、躯体功能评分显著高于单药组(P<0.05)。联合组患者消化道症状、手足综合征、骨髓抑制、神经毒性、皮肤症状发生率与单药组对比无明显差异(P>0.05)。联合组患者1年内生存率74.0%显著高于单药组40.0%(P<0.05)。结论对晚期直肠癌患者实施联合奥沙利铂同步放化疗的临床疗效优于卡培他滨单药同步放化疗,且可改善患者生活质量,延长患者生存期,不增加不良反应。
Objective To investigate the clinical efficacy of capecitabine alone or in combination with oxaliplatin in the treatment of advanced rectal cancer.Methods 100 patients with advanced rectal cancer admitted to our hospital from January 2013 to June 2017 were randomly divided into single drug group(n=50)and combined group(n=50).The single drug group was treated with capecitabine chemotherapy combined with concurrent radiotherapy,and the combined group was treated with capecitabine combined with oxaliplatin chemotherapy and concurrent radiotherapy.The impacts of the two therapies on treatment effects,body state,symptom improvement,quality of life,adverse reactions,and survival rate within 1 year were analyzed.Results The total effective rate of the combined group was 74.0%,which was significantly higher than that of the single drug group(42.0%)(P<0.05).The KPS score after treatment in the combined group was significantly higher than that in the single drug group(P<0.05).After treatment,the improvement of bloody stools,reduced times of stools,and pain in the sacrococcygeal region were significantly higher in the combined group than in the single drug group(P<0.05).The emotional function,role function,social function,cognitive function,and physical function scores after treatment were significantly higher in the combined group than in the single drug group(P<0.05).There was no significant difference in the incidence of gastrointestinal symptoms,hand-foot syndrome,myelosuppression,neurotoxicity and skin symptoms between the combined group and the single drug group(P>0.05).The survival rate of the combined group was 74.0%in 1 year,significantly higher than the 40.0%in the single drug group(P<0.05).Conclusion The clinical efficacy of capecitabine combined with oxaliplatin and concurrent chemoradiotherapy for advanced rectal cancer is superior to that of capecitabine alone and concurrent chemoradiotherapy,and can improve the quality of life of patients,and prolong the survival of patients,with no increased adverse reactions.
作者
饶春晖
陆淼炯
RAO Chunhui;LU Miaojiong(Department of Anorectal Medicine,Hangzhou Hospital of Traditional Chinese Medicine,Hangzhou310007,China)
出处
《中国现代医生》
2019年第9期73-76,共4页
China Modern Doctor
基金
浙江省医药卫生科技计划项目(2019KY522)
关键词
晚期直肠癌
卡培他滨
奥沙利铂
同步放化疗
Advanced rectal cancer
Capecitabine
Oxaliplatin
Concurrent chemoradiotherapy
